When is therapeutic drug monitoring of levetiracetam (Keppra) indicated and how should the serum level be interpreted?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 30, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Therapeutic Drug Monitoring of Levetiracetam (Keppra)

Routine therapeutic drug monitoring (TDM) of levetiracetam is NOT recommended for most patients, as the drug has predictable linear pharmacokinetics, minimal drug interactions, and a broad therapeutic window. 1

When TDM May Be Indicated

While the evidence explicitly states "no need for therapeutic drug monitoring" for levetiracetam 1, certain clinical scenarios warrant consideration:

Special Populations Where TDM May Be Useful:

  • Pregnancy: Levetiracetam clearance increases significantly during pregnancy, with levels declining as pregnancy progresses. One study showed 45 of 48 trough samples fell below the therapeutic range of 12-46 mg/L in pregnant women, with statistically significant differences between third and first trimesters 2, 3

  • Renal impairment: Levetiracetam clearance declines linearly with declining creatinine clearance. Patients with CrCL <60 mL/min require dose adjustments 4, 3, 5

  • Critically ill patients: May have augmented clearance requiring higher doses to maintain therapeutic levels 3

  • Pediatric patients: Clearance is 30-40% higher than adults, requiring weight-based dosing 3

  • Elderly patients (>65 years): Clearance decreased by almost 50% compared to adults 3

  • Patients on enzyme-inducing drugs: Co-administration with glucuronidation-inducing drugs increases clearance significantly 6

Therapeutic Reference Range

The accepted therapeutic reference range is 10-40 mg/L (or 12-46 mg/L in some references) 7, 8. However, this range has limited clinical utility because:

  • Wide variability exists in concentration-response relationships 8
  • No positive correlation has been consistently demonstrated between levetiracetam levels and efficacy or toxicity 3
  • Adverse effects, seizures, and efficacy occur below, within, and above the supposed reference ranges 3

Clinical Application

When TDM is performed, use it to:

  1. Verify compliance in patients with breakthrough seizures
  2. Detect severe intoxication (though rare given the drug's safety profile)
  3. Establish an individual therapeutic range in special populations where pharmacokinetics are altered 3

One study suggested a threshold concentration of 11 mg/L for therapeutic response (sensitivity 73%, specificity 71%), though this was not statistically significant due to small sample size and refractory seizure types 8.

Important Caveats

  • Monitor complete blood count rather than drug levels, as this is the recommended monitoring parameter 1
  • Dose adjustments in renal dysfunction are based on creatinine clearance, not serum levels 4
  • The FDA label makes no mention of routine TDM requirements 9
  • Levetiracetam is generally well-tolerated with minimal neuropsychiatric events (3.6% incidence in one study) 10

In practice, clinical response and tolerability should guide dosing decisions rather than serum concentrations for most patients. Reserve TDM for the specific populations listed above where altered pharmacokinetics are expected or when compliance is questioned.

References

Research

Therapeutic Drug Monitoring of Levetiracetam in Select Populations.

Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 2018

Research

Evaluation of Neuropsychiatric Events in Patients Receiving Levetiracetam for Seizure Prophylaxis Following Traumatic Brain Injury.

The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians, 2026

Related Questions

What is the appropriate management for a levetiracetam (Keppra) serum level of 54.6 µg/mL?
In an elderly male who recently transitioned to a skilled nursing facility and is taking levetiracetam (Keppra) 1000 mg twice daily, with a supratherapeutic serum concentration and no seizure activity or lethargy, when should the level be rechecked and should the dose be decreased?
What laboratory tests should be ordered for a patient on levetiracetam (Keppra)?
What is the appropriate dosing, renal dose adjustments, and monitoring for Keppra (levetiracetam)?
My Keppra (levetiracetam) level is 52 µg/mL (therapeutic range 10‑40 µg/mL) while I am taking 500 mg twice daily; what dose adjustment should I make?
Which statement about urinary tract infections is incorrect: (A) they can cause septic shock, (B) they are often accompanied by bacteremia, (C) the most common causative agent is Escherichia coli, (D) prophylaxis may be required for frequent recurrences, or (E) empiric therapy must always include coverage for Gram‑positive bacteria?
How long should aggressive isotonic fluid resuscitation be continued in a patient with elevated creatine kinase (CK)?
Do transdermal applications of estrogen and testosterone result in measurable serum hormone levels?
Can topical pramoxine be used for ulcerative colitis–associated diarrhea with rectal irritation and pain?
Is Lyrica (pregabalin) available in a 200 mg dosage?
When should immunoelectrophoresis be ordered in the evaluation of a suspected monoclonal gammopathy or plasma‑cell disorder?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.